Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
about
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphomaSystemic Front Line Therapy of Follicular Lymphoma: When, to Whom and HowThe Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective StudyLong term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphomaThe use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.Follicular Lymphoma: The Management of Elderly Patient.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan.
P2860
Q27000310-0F373E8B-3DFF-4EEB-97CE-37509EB76F28Q28073262-90EAEEA1-C7A0-4B1E-9437-6F223825E6FEQ33849498-6C263EAF-CFA1-4CB2-8F49-E4AB7E9E4764Q35786490-257F79EE-BA50-4E6E-AE5E-9529474B3BC4Q35867299-F8DF7DA9-0907-4520-8AA0-69158C11691FQ35956862-4F8E2F5D-CBF2-4BBC-A909-5CA9427D9EAFQ37045536-F3909D5F-F35D-4086-95CE-B3E80EF415A5Q37577856-6F671199-7723-4A9C-AC51-FAB230D62440Q38473731-DA3D4EEC-11E0-4BE0-AA52-36A105BAF0E6Q38510965-14B99179-F4CB-4F9E-9B81-C1B283E01936Q38530254-4CA62904-E0BA-4881-8AF9-D416BD7C6651Q48201625-3E71AEAC-B2F4-4805-A0CD-76A8D2F1434AQ51823821-32319178-2D70-41E7-8A0B-483DEC87DEB5
P2860
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@ast
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@en
type
label
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@ast
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@en
prefLabel
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@ast
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@en
P2093
P2860
P50
P356
P1476
Safety and efficacy of (90) yt ...... An Italian cooperative study.
@en
P2093
Adalberto Ibatici
Angelo M Carella
Barbara Botto
Chiara Ciochetto
Elena Ciabatti
Enrico Orciuolo
Gian Matteo Pica
Giulio Fraternali Orcioni
Mario Petrini
Nicola Cascavilla
P2860
P304
P356
10.1111/BJH.12695
P407
P577
2013-12-17T00:00:00Z